 |
市场调查报告书
商品编码
1424446
CD55 缺乏症（CHAPLE 症候群）治疗药物的全球市场：按类型、诊断、分销管道和地区划分Global Chaple Disease Therapeutics Market, By Type, By Diagnosis, By Distribution Channel, By Geography |
||||||
全球 CD55 缺乏症（CHAPLE 症候群）治疗市场规模预计将从 2024 年的 1.453 亿美元增加到 2031 年的 1.576 亿美元，年复合成长率（CAGR）1.2%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2023年 | 2023/2024年市场规模 | 1.453 亿美元 |
| 实际资料 | 2019年至2023年 | 预测期 | 2024-2031 |
| 预测期2023/2024~2030/2031年复合成长率： | 1.20% | 2030/2031价值预测 | 1.576 亿美元 |
Chapple 综合征，也称为 DAF 或 CD55 缺乏症，是指自然界中与免疫系统相关的一种罕见遗传疾病。 CHAPLE 是「血管病变血栓症、CD55 缺乏伴补体高活化和严重蛋白质丢失性肠道疾病 (PLE)」的缩写。这种疾病始于儿童时期，可能致命。 CD55 缺乏症（CHAPLE 症候群）治疗市场是指可用于治疗 Chapple 病的医疗选择。查普氏症是一种罕见的、慢性的、进行性的神经肌肉疾病，其特征是肌肉无力和无力。查普氏症无法治疗方法，治疗的目的是控制症状和提高生活品质。常见的治疗方法包括维持肌肉力量和活动能力的物理治疗、缓解疼痛和肌肉痉挛的药物、插入管子以协助营养和呼吸的手术以及脊椎支撑。有用于此目的的矫正器具和矫正器具。研究人员正在研究新的药物和基因疗法，这些疗法可能在未来减缓疾病的进展。全球 CD55 缺乏症（CHAPLE 症候群）治疗市场是由该疾病日益流行以及对有效治疗解决方案不断增长的需求所推动的。
市场动态：
由于开发新药和基因疗法的研究投资增加、患者支持团体提高的疾病意识以及新兴国家医疗成本的上升，全球 CD55 缺乏症（CHAPLE 综合征）治疗药物市场预计将增长。时期。然而，开发孤儿药的高成本和缺乏核准的治疗方法可能会限制市场扩张。另一方面，新的基因疗法有可能改变治疗格局并为市场相关人员提供机会。主要市场参与企业正在积极与研究机构合作，探索新的标靶和创新的治疗策略。
本研究的主要特点
- 本报告对全球CD55缺乏症（CHAPLE症候群）治疗药物市场进行了详细分析，并提出了以2023年为基准年的预测期（2024-2031年）的市场规模和年复合成长率（CAGR%） 。发表。
- 它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
- 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
- 主要公司概况包括Alexion Pharmaceuticals Inc.、Akari Therapeutics、Apellis Pharmaceuticals、Amgen Inc.、CinnaGen Co.、Novartis AG、F. Hoffmann-La Roche Ltd.、Regeneron Pharmaceuticals Inc. 和Alnylam Pharmaceuticals, Inc.。我可以列出它。
- 该报告的见解将使行销人员和公司负责人能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
- 全球 CD55 缺乏症（CHAPLE 综合征）治疗市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
- 透过用于分析全球肩胛骨疾病治疗药物市场的各种策略矩阵，将促进相关人员的决策。
目录
第一章 研究目的与前提
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map（COM）
第三章市场动态、法规及趋势分析
- 市场动态
- 扩大主要市场参与者之间的合作伙伴关係
- 核准时间长
- 医疗费用增加
- 主要亮点
- 监管场景
- 市场趋势
- PEST分析
- 波特的分析
- 产品发表会
- 合併、收购和合作
第四章全球 CD55 缺乏症（CHAPLE 症候群）治疗药物市场 - 冠状冠状病毒（COVID-19）大流行的影响
- 新型冠状病毒感染疾病（COVID-19）的流行病学
- 供需面分析
- 经济影响
第五章全球 CD55 缺乏症（CHAPLE 症候群）治疗药物市场（按类型），2019-2031 年
- Eculizumab
- 拉维利珠单抗
- 瓦波波斯
第六章 全球 CD55 缺乏症（CHAPLE 症候群）治疗药物市场（依诊断），2019-2031 年
- 胃肠道症状
- 浮肿
- 低白蛋白血症
- 低丙种球蛋白血症
- 营养不良
第七章全球 CD55 缺乏症（CHAPLE 症候群）治疗药物市场（依分销管道），2019-2031 年
- 零售药房
- 医院药房
- 网路药房
第8章2019-2031年全球CD55缺乏症（CHAPLE症候群）治疗药物市场（按地区）
- 北美洲
- 美国
- 加拿大
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 其他亚太地区
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 中东
- 海湾合作委员会国家
- 以色列
- 其他中东地区
- 非洲
- 北非
- 中部非洲
- 南非
第9章 竞争形势
- 公司简介
- Alexion Pharmaceuticals Inc.
- Akari Therapeutics
- Apellis Pharmaceuticals
- Amgen Inc.
- CinnaGen Co.
- Novartis AG
- Hoffmann-La Roche Ltd
- Regeneron Pharmaceuticals Inc.
- Alnylam Pharmaceuticals, Inc.
第10章
- 参考
- 调查方法
- 关于出版商
Global chaple disease therapeutics market size is expected to reach US$ 157.6 Mn by 2031 from US$ 145.3 Mn in 2024, exhibiting a compound annual growth rate (CAGR) of 1.2% during the forecast period.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2023/2024: | US$ 145.3 Mn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024-2031 |
| Forecast Period 2023/2024 to 2030/2031 CAGR: | 1.20% | 2030/2031 Value Projection: | US$ 157.6 Mn |
Chaple syndrome is also known as DAF or CD55 deficiency, which refers to a genetic disorder that is rare in nature and is related to the immune system. CHAPLE is an abbreviated form for 'CD55 deficiency with hyperactivation of angiopathic thrombosis, complement and severe protein-losing enteropathy (PLE)'. This disorder can be seen from childhood and could be fatal to the person. Chaple disease therapeutics market refers to the medical treatment options that are available for managing chaple disease. Chaple disease is a rare, chronic, and progressive neuromuscular disorder characterized by wasting and weakness of muscles. There is no cure for chaple disease and treatment aims to manage symptoms and improve quality of life. Some of the common treatment options include physical therapy to maintain strength and mobility, medications to relieve pain and muscle spasms, surgeries to insert tubes for delivering nutrition or breathing assistance, and bracing or adaptive devices to provide spinal support. Researchers are investigating new drug therapies and gene therapies which may slow the progression of disease in future. Global chaple disease therapeutics market is driven by growing prevalence of the disorder and rising demand for effective therapeutic solutions.
Market Dynamics:
Global chaple disease therapeutics market is expected witness steady growth during the forecast period due to increasing research investments for developing novel drugs and gene therapies, growing disease awareness through patient support organizations, and rising healthcare expenditures in developing nations. However, high costs that are associated with orphan drug development and lack of approved cure are likely to restrain market expansion. Meanwhile, emerging gene therapy approaches hold potential to alter the treatment landscape and provide opportunities for market players. Key market players are actively collaborating with research institutes to explore new targets and innovative treatment strategies.
Key features of the study:
- This report provides in-depth analysis of the global chaple disease therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global chaple disease therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies - Key companies covered as a part of this study include Alexion Pharmaceuticals Inc., Akari Therapeutics, Apellis Pharmaceuticals, Amgen Inc., CinnaGen Co., Novartis AG, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., and Alnylam Pharmaceuticals, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global chaple disease therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chaple disease therapeutics market
Detailed Segmentation:
- Global Chaple Disease Therapeutics Market, By Type
- Eculizumab
- Ravulizumab
- Veopoz
- Global Chaple Disease Therapeutics Market, By Diagnosis
- Gastrointestinal Symptoms
- Edema
- Hypoalbuminemia
- Hypogammaglobulinemia
- Malnutrition
- Global Chaple Disease Therapeutics Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Global Chaple Disease Therapeutics Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Top Companies in the Global Chaple Disease Therapeutics Market:
- Alexion Pharmaceuticals Inc.
- Akari Therapeutics
- Apellis Pharmaceuticals
- Amgen Inc.
- CinnaGen Co.
- Novartis AG
- Hoffmann-La Roche Ltd
- Regeneron Pharmaceuticals Inc.
- Alnylam Pharmaceuticals, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Type
- Market Snippet, By Diagnosis
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing partnerships among key market players
- Long approval timelines
- Rising healthcare expenditure
- Key Highlights
- Regulatory Scenario
- Market Trends
- PEST Analysis
- PORTER's Analysis
- Product Launches
- Mergers, Acquisitions, and Collaborations
4. Global Chaple Disease Therapeutics Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Chaple Disease Therapeutics Market, By Type, 2019-2031, (US$ Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Eculizumab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
- Ravulizumab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
- Veopoz
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
6. Global Chaple Disease Therapeutics Market, By Diagnosis, 2019-2031, (US$ Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Gastrointestinal Symptoms
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
- Edema
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
- Hypoalbuminemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
- Hypogammaglobulinemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
- Malnutrition
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
7. Global Chaple Disease Therapeutics Market, By Distribution Channel, 2019-2031, (US$ Mn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
8. Global Chaple Disease Therapeutics Market, By Region, 2019-2031, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020 -2031
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031,(US$ Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profile
- Alexion Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Akari Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Apellis Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- CinnaGen Co.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alnylam Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
10. Section
- References
- Research Methodology
- About us
